ALX Oncology Q2 Loss Narrows to $0.13/Share, Cash Runway Extended to H1 2028
ALXO has more than doubled off its 52-week low of $0.555.
Summary
ALX Oncology reported a narrower Q2 net loss of $17.97M ($0.13/share) driven by lower R&D and G&A costs, including reduced legacy trial spending and legal fees. The company also extended its cash runway guidance through H1 2028, a significant improvement from prior expectations. This follows the $50M debt facility secured in June, which bolstered the balance sheet. The results and extended runway reduce near-term dilution risk and support the lead program's advancement.
At the time of this announcement, ALXO was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.4M. The 52-week trading range was $0.56 to $2.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.